Slide 1: Exchange filing cover letter for analyst presentation
INDGN/SE/2025-26/100 January 29, 2026 BSE Limited, National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai- 400001, India. Mumbai – 400 051, India. Scrip Code: 544172 Trading symbol: INDGN Dear Sir / Mad
Slide 2: Investor Presentation Q3'26
Investor Presentation TM Q3’26
Slide 3: Disclaimer
Disclaimer This presentation may include opinions and assumptions about future performance which could be considered as forward-looking statements. Forward-looking statements intrinsically cover several risks and uncertainties, which may lead to a material difference between actual results and the s
Slide 4: Management Commentary on Q3 FY26 results
Management Commentary on Q3 FY26 results Manish Gupta Suhas Prabhu Chairman and Chief Executive Officer Chief Financial Officer We delivered a standout Q3 FY26, with revenue growing over 30% YoY and 17% During the quarter, we completed the acquisitions of BioPharm, a US-focused life sciences sequent
Slide 5: Q3 FY26: Financial Highlights
Q3 FY26: Financial Highlights Significant INR 9,421 M 30.8% YoY 24.4% YoY growth at scale Revenue from Operations 17.1% QoQ (INR) 15.1% QoQ (USD) Growing EBITDA / INR 1,747 M INR 1,026 M INR 13,954 M EBITDA(2) CASH (1) PAT impacted by PAT 15.7% YoY 19.6% QoQ 6.5% YoY 0.5% QoQ 7.5% YoY 10.0% QoQ non-
Slide 6: Q3 FY26: Business Highlights
Q3 FY26: Business Highlights Increasing 86 (76) 52 (40) 56% (63%) customer base Active Client Relationships Clients with $1 Revenue from Top 20 Global and scale-up Million+ Revenue Biopharma* Companies Global Delivery 5,497/4,737 27.4% 15.9% (5,245/4,523) (26.3%) (16.2%) Key metrics Total Employees
Slide 7: Q3 FY26: Segment Performance Update
Q3 FY26: Segment Performance Update Amount in INR Mn Segment performance QoQ Segment performance YTD 6,689 17,412 5,512 14,126 2,242 2,387 5,918 6,760 288 346 794 899 ECS EMS OTHERS ECS EMS OTHERS Q2 FY26 Q3 FY26 YTD FY25 YTD FY26 • Core segments (ECS & EMS) grew 17.0% QoQ in Q3FY26 and 20.5% YoY ov
Slide 8: Growth Approach 1: Deeper Engagement with Large Pharma Customers
Growth Approach 1: Deeper Engagement with Large Pharma Customers Amount in INR Mn Revenue from Top 5 customers Revenue from Top 20 customers 55% 49% 46% 40% 36% 86% 84% 84% 78% 74% 11,345 11,984 11,347 11,879 24,156 9,176 19,321 21,657 22,082 14,320 FY22 FY23 FY24 FY25 Q3 FY26 FY22 FY23 FY24 FY25 Q3
Slide 9: Growth Approach 2: Broader targeting leading to a wider, taller pyramid
Growth Approach 2: Broader targeting leading to a wider, taller pyramid 86 52 40 Active clients(1) $1Mn+ Clients(1) Active clients(1) added since FY22 Active client base(1) Successful track record of growing accounts 52 48* 3 3* 41 7 7* 34 35 2 28 3 8 4 3 4 6 86 80* 2 73 42 38* 62 63 46 26 26 31 23
Slide 10: Full-Stack Capabilities & GenAI Platforms Driving Operating Model Transformation
Full-Stack Capabilities & GenAI Platforms Driving Multi-Quarter Operating Model Transformation Full-Stack, Diverse Capabilities with Complex Skillsets • Consulting services & management of entire commercial Top 10 and marketing operations in US for a multi-product portfolio Omnichannel Pharma • Boos
Slide 11: Dual-Pronged Gen AI Strategy
Dual-Pronged Gen AI Strategy: Accelerate value for clients today while building for tomorrow Existing Products New Products Extend capabilities of existing products to capture more Unlock value from new avenues that have opened up EXTEND value via cross-sell/up-sell (New Gen AI features) BUILD due t
Slide 12: AI-Led Innovation across Commercial Value Chain
AI-Led Innovation across Commercial Value Chain Strategy & Brand Planning Content Evolution Content Studio Content Operations & Deployment Brand Planning Evolution Localization Omnichannel Defining the strategic Evolve brand concept Localize Creative Content Orchestration direction of the brand and
Slide 13: Enhancing credibility with industry recognition
Enhancing credibility with industry recognition Indegene recognised among the Best Companies for Women in India with a Hall of Fame distinction by Avtar – Leaders in Workplace Culture and Inclusion and Seramount Indegene was awarded the Silver Medal by EcoVadis for its Environmental, Social, and Gov
Slide 14: Financial Highlights
Financial Highlights © 2026 Indegene. All rights reserved. 13
Slide 15: Q3 FY26: Consolidated & Ex-BioPharm Financials
Q3 FY26: Consolidated & Ex-BioPharm Financials Amount in INR Mn Consolidated BioPharm* Prior QTR Prior Year Consolidated Ex-BioPharm Particulars Q3 FY26 Q3 FY26 Q2 FY26 Q3 FY25 QoQ% YoY% QoQ% YoY% Revenue from Operations 9,421 902 8,042 7,204 17.1% 30.8% 5.9% 18.3% Employee Benefit Expenses 5,681 34
Slide 16: Q3 FY26: Operating Performance
Q3 FY26: Operating Performance Amount in INR Mn Particulars Revenues Adj. EBITDA Adj. PBT Adj. PAT Amount (INR Mn)% 9,421 1,747 1,460 1,106 18.5% 15.4% 11.7% *Adjusted financials exclude non-operating one-time expenses of INR 105mn in EBITDA & PBT and 80mn net of tax in PAT © 2025 Indegene. All righ
Slide 17: Significant Accounting Matters
Significant Accounting Matters Amount in INR Mn Amortisation schedule Amortization Total Particulars from newly Amortization acquired entities Q3 FY'26 150 241 Q4 FY'26* 156 238 Q1 FY'27 159 240 Q2 FY'27 159 239 48MN Q3 FY'27 115 191 Q4 FY'27 115 191 Q1 FY'28 115 191 Q2 FY'28 115 191 24MN Q3 FY'28 1
Slide 18: Q3 FY26: Stable Business mix
Q3 FY26: Stable Business mix Revenue from Service offering ($Mn) Revenue by Customer Industry (%)* Revenue by Customer Geography (%) 4.2% 2.5% 85.2 92.2 106.1 3.4% 3.6% 3.6% 3.7% 2.3% 25.8% 71.5% 67.9% 68.5% 71.0% 0.4% 89.9% 28.5% 27.9% 25.3% Q3 FY25 Q2 FY26 Q3 FY26 Q3 FY26 Q3 FY26 Enterprise Medica
Slide 19: Thank You!
Thank You! www.indegene.com
Slide 20: Fact Sheet
Fact Sheet Consolidated Financial Data - Third Quarter, Fiscal 2026 Operational & Financial Metrics Key performance indicators (in INR Mn) Quarter ended Growth SI. Particulars Dec 31, Sep 30, Dec 31, No. YoY QoQ 2025 2025 2024 1. Active clients (1) (No.) 86 76 75 2. Revenue from operations 9,421 8,0
Slide 21: Fact Sheet
Fact Sheet Consolidated Financial Data - Third Quarter, Fiscal 2026 Revenue by customer industry (in %) Quarter ended (contribution) Growth Particulars Dec 31, Sep 30, Dec 31, YoY QoQ 2025 2025 2024 Biopharma 89.9 92.0 93.7 25.4 14.5 Medical Devices 4.2 3.5 2.6 112.2 44.1 Emerging Biotech 3.4 3.1 2.